Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CRISPR01:59

CRISPR

49.8K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
49.8K
CRISPR and crRNAs02:53

CRISPR and crRNAs

16.9K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
16.9K
Homologous Recombination02:31

Homologous Recombination

50.3K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
50.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

USP Gene Network Modulation and Osmoprotection Define Salt Resilience in Chenopodium quinoa Genotypes.

Scientific reports·2026
Same author

Ondansetron derivatives as potential PTP1B inhibitors for treating type 2 diabetes mellitus: <i>in silico</i>, <i>in vitro</i>, and <i>in vivo</i> analysis.

Frontiers in pharmacology·2026
Same author

Efficacy and safety of once-weekly insulin efsitora alfa versus daily basal insulin analogs in type 2 diabetes: a systematic review and meta-analysis.

Annals of medicine and surgery (2012)·2026
Same author

A minimal transcription factor network is sufficient to drive paclitaxel biosynthesis.

Science advances·2026
Same author

Integrated morpho-physiological, metabolomic and transcriptomic profiling uncovers ethylene-mediated metabolic regulation shaping drought resilience in wheat.

BMC plant biology·2026
Same author

Radiation therapy plus osimertinib <i>vs</i> osimertinib alone in epidermal growth factor receptor mutated non-small cell lung cancer: A systematic review.

World journal of methodology·2026
Same journal

Artificial intelligence-driven multi-omics analysis of gut-kidney axis in chronic kidney disease.

Progress in molecular biology and translational science·2026
Same journal

Artificial intelligence in multi-omics analysis of heart diseases.

Progress in molecular biology and translational science·2026
Same journal

AI in multi-omics analysis of type 2 diabetes.

Progress in molecular biology and translational science·2026
Same journal

AI in multi-omics analysis in AMR.

Progress in molecular biology and translational science·2026
Same journal

AI in multi-omics analysis of COVID-19 patient data.

Progress in molecular biology and translational science·2026
Same journal

AI in multi-omics analysis of liver diseases.

Progress in molecular biology and translational science·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2025

Genome Editing in Mammalian Cell Lines using CRISPR-Cas
07:56

Genome Editing in Mammalian Cell Lines using CRISPR-Cas

Published on: April 11, 2019

21.6K

Current progress in CRISPR-Cas systems for cancer.

Hunaiza Fatima1, Hajra Ali Raja2, Rabia Amir3

  • 1Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan; Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.

Progress in Molecular Biology and Translational Science
|September 12, 2024
PubMed
Summary
This summary is machine-generated.

CRISPR gene editing offers new cancer treatments by targeting genetic factors. This technology aids in developing precise therapies and overcoming treatment resistance for better patient outcomes.

Keywords:
CAR-TCRISPR-CasCancerGenome editingTumor

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

199
Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
10:21

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

Published on: January 5, 2018

13.1K

Related Experiment Videos

Last Updated: Jun 13, 2025

Genome Editing in Mammalian Cell Lines using CRISPR-Cas
07:56

Genome Editing in Mammalian Cell Lines using CRISPR-Cas

Published on: April 11, 2019

21.6K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

199
Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
10:21

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

Published on: January 5, 2018

13.1K

Area of Science:

  • Oncology
  • Genetics
  • Biotechnology

Background:

  • Cancer remains a leading cause of global mortality, with increasing incidence.
  • Traditional treatments like chemotherapy and radiation have limitations.
  • Gene therapy and immunotherapy represent advanced cancer treatment modalities.

Purpose of the Study:

  • To explore the revolutionary impact of CRISPR-Cas gene editing technology in cancer research.
  • To highlight CRISPR's role in identifying therapeutic targets and understanding oncogenesis.
  • To discuss CRISPR's potential in developing novel, precise, and potent cancer therapies.

Main Methods:

  • CRISPR-Cas genome editing for target identification and gene manipulation.
  • Application of CRISPR in interrupting oncogenes and activating tumor suppressor genes.
  • Utilizing CRISPR in conjunction with chimeric antigen receptor (CAR) T cells for targeted cancer therapy.

Main Results:

  • CRISPR facilitates the identification of genetic factors contributing to cancer development and treatment resistance.
  • CRISPR enables the activation of tumor suppressor genes, enhancing cancer cell susceptibility to therapies.
  • CRISPR-based strategies, including CAR T cells, show promise for personalized cancer treatment.

Conclusions:

  • CRISPR-Cas technology is a powerful tool driving significant advancements in cancer research.
  • CRISPR offers new avenues for overcoming resistance to existing cancer treatments.
  • The technology holds immense potential for developing next-generation, precise cancer therapies.